Real-World study checks if benralizumab tames severe asthma in taiwan

NCT ID NCT05734339

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 43 adults in Taiwan with severe eosinophilic asthma who were already prescribed benralizumab. Researchers tracked changes in asthma control using a standard questionnaire over time. The goal was to see how well the drug works in everyday medical practice, not just in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: benralizumab
What this could lead to: If successful, this study could show that benralizumab helps control severe asthma in real-world settings in Taiwan.
What could go wrong: This is a small, completed observational study with no control group, so results may not apply broadly. It does not test a new treatment, only confirms existing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Research Site

Changhua, Taiwan
Research Site

Kaohsiung City, Taiwan
Research Site

New Taipei City, Taiwan
Research Site

Tainan, Taiwan
Research Site

Taipei, Taiwan
Research Site

Taoyuan City, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.